
Joel A Sincavage
Supervisory Patent Examiner (ID: 11124, Phone: (571)272-2610 , Office: P/2910 )
Most Active Art Unit | 2911 |
Art Unit(s) | 2911, 2900, 2901, 2910 |
Total Applications | 4082 |
Issued Applications | 4006 |
Pending Applications | 1 |
Abandoned Applications | 75 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 4826840
[patent_doc_number] => 20080125384
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2008-05-29
[patent_title] => 'SIMULTANEOUS SILENCING AND RESTORATION OF GENE FUNCTION'
[patent_app_type] => utility
[patent_app_number] => 11/562281
[patent_app_country] => US
[patent_app_date] => 2006-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 4816
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0125/20080125384.pdf
[firstpage_image] =>[orig_patent_app_number] => 11562281
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/562281 | SIMULTANEOUS SILENCING AND RESTORATION OF GENE FUNCTION | Nov 20, 2006 | Abandoned |
Array
(
[id] => 5480808
[patent_doc_number] => 20090203765
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-08-13
[patent_title] => 'MODULATION OF EIF4E-BP2 EXPRESSION'
[patent_app_type] => utility
[patent_app_number] => 12/094598
[patent_app_country] => US
[patent_app_date] => 2006-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29315
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0203/20090203765.pdf
[firstpage_image] =>[orig_patent_app_number] => 12094598
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/094598 | Modulation of eIF4E-BP2 expression | Nov 20, 2006 | Issued |
Array
(
[id] => 9239200
[patent_doc_number] => 08603991
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2013-12-10
[patent_title] => 'Individualized cancer therapy'
[patent_app_type] => utility
[patent_app_number] => 11/601431
[patent_app_country] => US
[patent_app_date] => 2006-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 35
[patent_figures_cnt] => 33
[patent_no_of_words] => 17409
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 328
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 11601431
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/601431 | Individualized cancer therapy | Nov 16, 2006 | Issued |
Array
(
[id] => 5056914
[patent_doc_number] => 20070059836
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2007-03-15
[patent_title] => 'Compositions and methods for regulating genes of interest'
[patent_app_type] => utility
[patent_app_number] => 11/595104
[patent_app_country] => US
[patent_app_date] => 2006-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 6775
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0059/20070059836.pdf
[firstpage_image] =>[orig_patent_app_number] => 11595104
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/595104 | Compositions and methods for regulating genes of interest | Nov 8, 2006 | Abandoned |
Array
(
[id] => 314860
[patent_doc_number] => 07524830
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2009-04-28
[patent_title] => 'Decoy-containing pharmaceutical compositions and method of using the same'
[patent_app_type] => utility
[patent_app_number] => 11/580748
[patent_app_country] => US
[patent_app_date] => 2006-10-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 7476
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/524/07524830.pdf
[firstpage_image] =>[orig_patent_app_number] => 11580748
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/580748 | Decoy-containing pharmaceutical compositions and method of using the same | Oct 11, 2006 | Issued |
Array
(
[id] => 4477390
[patent_doc_number] => 07906490
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2011-03-15
[patent_title] => 'Circular DNA vectors for synthesis of RNA and DNA'
[patent_app_type] => utility
[patent_app_number] => 11/523884
[patent_app_country] => US
[patent_app_date] => 2006-09-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 23
[patent_no_of_words] => 28647
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/906/07906490.pdf
[firstpage_image] =>[orig_patent_app_number] => 11523884
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/523884 | Circular DNA vectors for synthesis of RNA and DNA | Sep 19, 2006 | Issued |
Array
(
[id] => 4983428
[patent_doc_number] => 20070087987
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2007-04-19
[patent_title] => 'Modulation of glucagon receptor expression'
[patent_app_type] => utility
[patent_app_number] => 11/524041
[patent_app_country] => US
[patent_app_date] => 2006-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14775
[patent_no_of_claims] => 40
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0087/20070087987.pdf
[firstpage_image] =>[orig_patent_app_number] => 11524041
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/524041 | Modulation of glucagon receptor expression | Sep 18, 2006 | Abandoned |
Array
(
[id] => 8164506
[patent_doc_number] => 08173612
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2012-05-08
[patent_title] => 'Chemotherapy involving antisense oligonucleotides for preventing and/or treating pulmonary fibrosis'
[patent_app_type] => utility
[patent_app_number] => 11/521843
[patent_app_country] => US
[patent_app_date] => 2006-09-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3108
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 131
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/08/173/08173612.pdf
[firstpage_image] =>[orig_patent_app_number] => 11521843
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/521843 | Chemotherapy involving antisense oligonucleotides for preventing and/or treating pulmonary fibrosis | Sep 14, 2006 | Issued |
Array
(
[id] => 4682815
[patent_doc_number] => 20080249041
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2008-10-09
[patent_title] => 'Formulations comprising antisense nucleotides to connexins'
[patent_app_type] => utility
[patent_app_number] => 11/512725
[patent_app_country] => US
[patent_app_date] => 2006-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 19
[patent_no_of_words] => 10784
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0249/20080249041.pdf
[firstpage_image] =>[orig_patent_app_number] => 11512725
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/512725 | Formulations comprising antisense nucleotides to connexins | Aug 28, 2006 | Abandoned |
Array
(
[id] => 5107677
[patent_doc_number] => 20070066555
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2007-03-22
[patent_title] => 'Formulations comprising antisense nucleotides to connexins'
[patent_app_type] => utility
[patent_app_number] => 11/512728
[patent_app_country] => US
[patent_app_date] => 2006-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 10590
[patent_no_of_claims] => 43
[patent_no_of_ind_claims] => 15
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0066/20070066555.pdf
[firstpage_image] =>[orig_patent_app_number] => 11512728
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/512728 | Formulations comprising antisense nucleotides to connexins | Aug 28, 2006 | Abandoned |
Array
(
[id] => 5172386
[patent_doc_number] => 20070072819
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2007-03-29
[patent_title] => 'Formulations comprising antisense nucleotides to connexins'
[patent_app_type] => utility
[patent_app_number] => 11/512730
[patent_app_country] => US
[patent_app_date] => 2006-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 10774
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0072/20070072819.pdf
[firstpage_image] =>[orig_patent_app_number] => 11512730
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/512730 | Formulations comprising antisense nucleotides to connexins | Aug 28, 2006 | Abandoned |
Array
(
[id] => 5172387
[patent_doc_number] => 20070072820
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2007-03-29
[patent_title] => 'Formulations comprising antisense nucleotides to connexins'
[patent_app_type] => utility
[patent_app_number] => 11/512735
[patent_app_country] => US
[patent_app_date] => 2006-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 10787
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0072/20070072820.pdf
[firstpage_image] =>[orig_patent_app_number] => 11512735
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/512735 | Formulations comprising antisense nucleotides to connexins | Aug 28, 2006 | Issued |
Array
(
[id] => 4460770
[patent_doc_number] => 07879811
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2011-02-01
[patent_title] => 'Formulations comprising antisense nucleotides to connexins'
[patent_app_type] => utility
[patent_app_number] => 11/510498
[patent_app_country] => US
[patent_app_date] => 2006-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 19
[patent_no_of_words] => 10793
[patent_no_of_claims] => 153
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/879/07879811.pdf
[firstpage_image] =>[orig_patent_app_number] => 11510498
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/510498 | Formulations comprising antisense nucleotides to connexins | Aug 24, 2006 | Issued |
Array
(
[id] => 5136474
[patent_doc_number] => 20070078103
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2007-04-05
[patent_title] => 'Formulations comprising antisense nucleotides to connexins'
[patent_app_type] => utility
[patent_app_number] => 11/510496
[patent_app_country] => US
[patent_app_date] => 2006-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 10774
[patent_no_of_claims] => 41
[patent_no_of_ind_claims] => 16
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0078/20070078103.pdf
[firstpage_image] =>[orig_patent_app_number] => 11510496
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/510496 | Formulations comprising antisense nucleotides to connexins | Aug 24, 2006 | Issued |
Array
(
[id] => 1077027
[patent_doc_number] => 07615540
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2009-11-10
[patent_title] => 'Formulations comprising antisense nucleotides to connexins'
[patent_app_type] => utility
[patent_app_number] => 11/510280
[patent_app_country] => US
[patent_app_date] => 2006-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 19
[patent_no_of_words] => 10784
[patent_no_of_claims] => 83
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/615/07615540.pdf
[firstpage_image] =>[orig_patent_app_number] => 11510280
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/510280 | Formulations comprising antisense nucleotides to connexins | Aug 24, 2006 | Issued |
Array
(
[id] => 5496474
[patent_doc_number] => 20090264502
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-10-22
[patent_title] => 'COMPOSITIONS AND THEIR USES DIRECTED TO HSP27'
[patent_app_type] => utility
[patent_app_number] => 12/064330
[patent_app_country] => US
[patent_app_date] => 2006-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8120
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0264/20090264502.pdf
[firstpage_image] =>[orig_patent_app_number] => 12064330
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/064330 | COMPOSITIONS AND THEIR USES DIRECTED TO HSP27 | Aug 23, 2006 | Abandoned |
Array
(
[id] => 5242872
[patent_doc_number] => 20070021367
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2007-01-25
[patent_title] => 'Modulation of SOCS-3 expression'
[patent_app_type] => utility
[patent_app_number] => 11/505720
[patent_app_country] => US
[patent_app_date] => 2006-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21334
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0021/20070021367.pdf
[firstpage_image] =>[orig_patent_app_number] => 11505720
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/505720 | Modulation of SOCS-3 expression | Aug 16, 2006 | Abandoned |
Array
(
[id] => 6579740
[patent_doc_number] => 20100273997
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-10-28
[patent_title] => 'Ribozyme to cleave coronavirus gene'
[patent_app_type] => utility
[patent_app_number] => 11/501049
[patent_app_country] => US
[patent_app_date] => 2006-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 4786
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0273/20100273997.pdf
[firstpage_image] =>[orig_patent_app_number] => 11501049
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/501049 | Ribozyme to cleave coronavirus gene | Aug 8, 2006 | Abandoned |
Array
(
[id] => 5887671
[patent_doc_number] => 20060275300
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2006-12-07
[patent_title] => 'P450RAI-2 (P450 cytochrome 26B), encoding nucleic acid molecules and methods and uses thereof'
[patent_app_type] => utility
[patent_app_number] => 11/498250
[patent_app_country] => US
[patent_app_date] => 2006-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 38
[patent_figures_cnt] => 38
[patent_no_of_words] => 39700
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0275/20060275300.pdf
[firstpage_image] =>[orig_patent_app_number] => 11498250
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/498250 | P450RAI-2 (P450 cytochrome 26B), encoding nucleic acid molecules and methods and uses thereof | Aug 2, 2006 | Issued |
Array
(
[id] => 32713
[patent_doc_number] => 07790694
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2010-09-07
[patent_title] => 'Antisense antibacterial method and compound'
[patent_app_type] => utility
[patent_app_number] => 11/487009
[patent_app_country] => US
[patent_app_date] => 2006-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 29
[patent_no_of_words] => 18757
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 200
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/790/07790694.pdf
[firstpage_image] =>[orig_patent_app_number] => 11487009
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/487009 | Antisense antibacterial method and compound | Jul 12, 2006 | Issued |